Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020

Rhea-AI Summary

Passage Bio (NASDAQ: PASG) announced a conference call and live webcast scheduled for 8:30 a.m. ET on November 10, 2020, to discuss its Q3 2020 financial results and recent business highlights. The call can be accessed by dialing 833-528-0605 (domestic) or 830-221-9711 (international) with conference ID 8478507. The archived webcast will be available for 30 days post-event. The company focuses on gene therapies for rare CNS disorders and collaborates with the University of Pennsylvania’s Gene Therapy Program.

Positive

• Strategic collaboration with University of Pennsylvania enhances research capabilities.
• Focus on rare, monogenic CNS disorders presents niche market opportunities.

Negative

• None.

PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 10, 2020 to report its third quarter 2020 financial results and discuss recent business highlights.

To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-9711 (international) and refer to conference ID 8478507. A live audio webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call.

About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with unparalleled access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Investors:
Sarah McCabe and Zofia Mita
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com
zofia.mita@sternir.com

Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com

FAQ

When will Passage Bio release its Q3 2020 financial results?

Passage Bio will release its Q3 2020 financial results on November 10, 2020.

How can I participate in the Passage Bio conference call?

You can participate by calling 833-528-0605 (domestic) or 830-221-9711 (international) with conference ID 8478507.

Where can I find the archived webcast of the Passage Bio call?

The archived webcast will be available on Passage Bio's website approximately two hours after the event.

What is the focus of Passage Bio's gene therapies?

Passage Bio focuses on gene therapies for rare, monogenic central nervous system disorders.

Who does Passage Bio collaborate with for its research?

Passage Bio has a strategic collaboration with the University of Pennsylvania's Gene Therapy Program.